Advanced search
Publication Cover
Expert Review of Respiratory Medicine Volume 10, 2016 - Issue 2
Submit an article Journal homepage
358
Views
13
CrossRef citations to date
0
Altmetric
Reviews

Addressing corticosteroid insensitivity in adults with asthma

Neil C. ThomsonInstitute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, UKCorrespondence[email protected]
Pages 137-156 | Received 29 Oct 2015, Accepted 14 Dec 2015, Published online: 28 Jan 2016

References

  • Papers of special note have been highlighted as:
  • • of interest
  • •• of considerable interest
  • GINA Report. Global strategy for asthma management and prevention 2014. [cited 2015 Oct 11]. Available from: http://www.ginasthma.com.
  • British guideline on the management of asthma. A national clinical guideline. Thorax. 2014;1–180. [ cited 2015 Oct 11]. Available from: www.sign.ac.uk.
  • Adams N, Bestall J, Jones P, et al. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Systematic Rev. 2008;4 Art. No.: CD003534doi:10.1002/14651858.CD003534.pub3
  • Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170(8):836–844.
  • Travers J, Marsh S, Williams M, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax. 2007;62(3):219–223.
  • Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999;130(6):487–495.
  • Colice GL, Stampone P, Leung DYM, et al. Oral corticosteroids in poorly controlled asthma. J Allergy Clin Immunol. 2005;115(1):200–201.
  • Szefler SJ, Martin RJ. Lessons learned from variation in response to therapy in clinical trials. J Allergy Clin Immunol. 2010;125(2):285–4.
  • Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis. Arch Intern Med. 1999;159(9):941–955.
  • Lapi F, Kezouh A, Suissa S, et al. The use of inhaled corticosteroids and the risk of adrenal insufficiency. Eur Respir J. 2013;42(1):79–86.
  • Ernst P, Suissa S. Systemic effects of inhaled corticosteroids. Curr Opin Pulm Med. 2012;18(1):85–89.
  • Clemmer GL, Wu AC, Rosner B, et al. Measuring the corticosteroid responsiveness endophenotype in asthmatic patients. J Allergy Clin Immunol. 2015;136(2):274-81.e8.

•• A composite phenotype that includes information on inhaled corticosteroid treatment response in patients with mild-to-moderate asthma assessed by six outcomes (lung function, bronchodilator response, airway responsiveness, symptoms, need for oral corticosteroids, and frequency of emergency department visits and hospitalizations) is reported to identify endophenotypes that more accurately describe corticosteroid sensitivity and insensitivity.

  • Woodruff PG, Modrek B, Choy DF, et al. T-helper Type 2-driven Inflammation Defines Major Subphenotypes of Asthma. Am J Respir Crit Care Med. 2009;180(5):388–395.
  • Cowan DC, Taylor DR, Peterson LE, et al. Biomarker-based asthma phenotypes of corticosteroid response. J Allergy Clin Immunol. 2015;135:877-83.e1.
  • Kelly MM, King EM, Rider CF, et al. Corticosteroid-induced gene expression in allergen-challenged asthmatic subjects taking inhaled budesonide. Br J Pharmacol. 2012;165(6):1737–1747.
  • Van Der Schee MP, Palmay R, Cowan JO, et al. Predicting steroid responsiveness in patients with asthma using exhaled breath profiling. Clin Exp Allergy. 2013;43(11):1217–1225.
  • Livingston E, Chaudhuri R, McMahon AD, et al. Systemic sensitivity to corticosteroids in smokers with asthma. Eur Respir J. 2007;29(1):64–71.
  • Maranville JC, Baxter SS, Torres JM, et al. Inter-ethnic differences in lymphocyte sensitivity to glucocorticoids reflect variation in transcriptional response. Pharmacogenomics. 2013;13(2):121–129.
  • Chun E, Lee H-S, Bang B-R, et al. Dexamethasone-induced FKBP51 expression in peripheral blood mononuclear cells could play a role in predicting the response of asthmatics to treatment with corticosteroids. J Clin Immunol. 2011;31(1):122–127.
  • Goleva E, Jackson LP, Gleason M, et al. Usefulness of PBMCs to predict clinical response to corticosteroids in asthmatic patients. J Allergy Clin Immunol. 2012;129(3):687–693.
  • The Childhood Asthma Management Program Research G. Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med. 2000;343(15):1054–1063.
  • Tantisira KG, Hwang ES, Raby BA, et al. TBX21: A functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004;101(52):18099–18104.
  • Tantisira K, Lake S, Silverman E, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet. 2004;13:1353–1359.
  • Tantisira KG, Silverman ES, Mariani TJ, et al. FCER2: A pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol. 2007;120(6):1285–1291.
  • Tantisira KG, Lasky-Su J, Harada M, et al Genomewide Association between GLCCI1 and Response to Glucocorticoid Therapy in Asthma. N Eng J Med. 2011;365(13):1173–1183.
  • Tantisira KG, Damask A, Szefler SJ, et al. Genome-wide Association Identifies the T Gene as a Novel Asthma Pharmacogenetic Locus. Am J Respir Crit Care Med. 2012;185(12):1286–1291.
  • Wang Y, Tong C, Wang Z, et al. Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma. Pharmacogenomics J. 2015;15(5):422–429.
  • Sharma S, Kho AT, Chhabra D, et al. Glucocorticoid genes and the developmental origins of asthma susceptibility and treatment response. Am J Respir Cell Mol Biol. 2015;52(5):543–553.
  • Chalmers GW, Macleod KJ, Little SA, et al. Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax. 2002;57(3):226–230.
  • Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med. 2007;175(8):783–790.
  • Chaudhuri R, Livingston E, McMahon AD, et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am J Respir Crit Care Med. 2003;168(11):1308–1311.
  • Polosa R, Thomson NC. Smoking and asthma: dangerous liaisons. Eur Respir J. 2013;41(3):716–726.

•• Provides an overview of recent evidence on the harmful effects of smoking in asthma, possible underlying inflammatory mechanisms for this altered response, management options for these patients, and potential future therapeutic directions.

  • Tomlinson JEM, McMahon AD, Chaudhuri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005;60(4):282–287.
  • Telenga E, Kerstjens H, Ten Hacken N, et al. van den Berge M. Inflammation and corticosteroid responsiveness in ex-, current- and never-smoking asthmatics. BMC Pulm Med. 2013;13(1):58.
  • Dijkstra A, Vonk JM, Jongepier H, et al. Lung function decline in asthma: association with inhaled corticosteroids, smoking and sex. Thorax. 2006;61(2):105–110.
  • Lange P, Scharling H, Ulrik CS, et al. Inhaled corticosteroids and decline of lung function in community residents with asthma. Thorax. 2006;61(2):100–104.
  • O’Byrne PM, Lamm CJ, Busse WW, et al. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. Chest. 2009;136(6):1514–1520.
  • Cohen RT, Raby BA, Van Steen K, et al. In utero smoke exposure and impaired response to inhaled corticosteroids in children with asthma. J Allergy Clin Immunol. 2010;126(3):491–497.
  • Nimmagadda S, Szefler S, Spahn J, et al. Allergen exposure decreases glucocorticoid receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med. 1997;155:87–93.
  • Larsson S, Hansson L, Greiff L, et al Natural allergen exposure does not diminish the sensitivity of cytokine production to glucocorticoids in blood cells of seasonal allergic asthma and rhinitis patients. Resp Med. 2002;96:927–933.
  • Castanhinha S, Sherburn R, Walker S, et al. Pediatric severe asthma with fungal sensitization is mediated by steroid-resistant IL-33. J Allergy Clin Immunol. 2015;136(2):312-22.e7.
  • Li L-B, Goleva E, Hall CF, et al. Superantigen-induced corticosteroid resistance of human T cells occurs through activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK-ERK) pathway. J Allergy Clin Immunol. 2004;114(5):1059–1069.
  • Fakhri S, Tulic M, Christodoulopoulos P, et al. Microbial superantigens induce glucocorticoid receptor beta and steroid resistance in a nasal explant model. Laryngoscope. 2004;114:887–892.
  • Goleva E, Jackson LP, Harris JK, et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am J Respir Crit Care Med. 2013;188(10):1193–1201.
  • Goleva E, Hauk PJ, Hall CF, et al. Corticosteroid-resistant asthma is associated with classical antimicrobial activation of airway macrophages. J Allergy Clin Immunol. 2008;122(3):550-9.e3.
  • Hadebe S, Kirstein F, Fierens K, et al Microbial ligand costimulation drives neutrophilic steroid-refractory asthma. PLoS ONE. 2015;10(8):e0134219.
  • Ducharme FM, Lemire C, Noya FJD, et al. Preemptive use of high-dose fluticasone for virus-induced wheezing in young children. N Eng J Med. 2009;360(4):339–353.
  • Papi A, Contoli M, Adcock IM, et al. Rhinovirus infection causes steroid resistance in airway epithelium through nuclear factor κB and c-Jun N-terminal kinase activation. J Allergy Clin Immunol. 2013;132(5):1075–1085.
  • Footitt J, Mallia P, Durham AL, et al. Oxidative and nitrosative stress and histone deacetylase-2 activity in exacerbations of chronic obstructive pulmonary disease. Chest. 2015; doi:10.1378/chest.14-2637 Epub ahead of print
  • McSharry C, Spears M, Chaudhuri R, et al. Increased sputum endotoxin levels are associated with an impaired lung function response to oral steroids in asthmatic patients. J Allergy Clin Immunol. 2014;134(5):1068–1075.

• Increased sputum endotoxin concentrations are associated with an impaired lung function response to oral corticosteroids, particularly in never smokers with asthma, which suggests that airway endotoxin may contribute to corticosteroid insensitivity in asthma.

  • Sutherland ER, Goleva E, Jackson LP, et al. Vitamin D levels, lung function, and steroid response in adult asthma. Am J Respir Crit Care Med. 2010;181(7):699–704.
  • Pavord I, Brightling C, Woltmann G, et al. Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999;353:2213–2214.
  • McGrath KW, Icitovic N, Boushey HA, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012;185(6):612–619.
  • Chung EH, Jia Y, Ohnishi H, et al. LeukotrieneB4 receptor 1 is differentially expressed on peripheral T cells of steroid-sensitive and -resistant asthmatics. Ann Allergy Asthma Immunol. 2014;112(3):211–216.e1.
  • Bourdin A, Kleis S, Chakra M, et al. Limited short-term steroid responsiveness is associated with thickening of bronchial basement membrane in severe asthma. Chest. 2012;141(6):1504–1511.
  • Heaney LG, Horne R. Non-adherence in difficult asthma: time to take it seriously. Thorax. 2012;67(3):268–270.
  • Williams LK, Peterson EL, Wells K, et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J Allergy Clin Immunol. 2011;128(6):1185–1191.
  • Gamble J, Stevenson M, McClean E, et al. The prevalence of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2009;180(9):817–822.
  • Haczku A, Panettieri RA Jr. Social stress and asthma: The role of corticosteroid insensitivity. J Allergy Clin Immunol. 2010;125(3):550–558.
  • Federico MJ, Covar RA, Brown EE, et al. Racial differences in T-lymphocyte response to glucocorticoids. Chest. 2005;127(2):571–578.
  • Dunn RM, Lehman E, Chinchilli VM, et al. Impact of age and sex on response to asthma therapy. Am J Respir Crit Care Med. 2015;192:551–558.

• In Asthma Clinical Research Network (ACRN) trials in nonsmokers with mild-to-moderate asthma, treatment failures (worsening asthma resulting in systemic corticosteroid use, hospitalization, emergency department visit, prolonged decrease in PEF, increase in albuterol use, or safety concerns including exacerbations) increased for every year above age 30 years in participants receiving inhaled corticosteroids.

  • Wechsler ME, Castro M, Lehman E, et al. Impact of race on asthma treatment failures in the Asthma Clinical Research Network. Am J Respir Crit Care Med. 2011;184(11):1247–1253.
  • Gould W, Peterson EL, Karungi G, et al. Factors predicting inhaled corticosteroid responsiveness in African American patients with asthma. J Allergy Clin Immunol. 2010;126(6):1131–1138.
  • Boulet L-P, Franssen E. Influence of obesity on response to fluticasone with or without salmeterol in moderate asthma. Respir Med. 2007;101(11):2240–2247.
  • Sutherland ER, Lehman EB, Teodorescu M, et al. Body mass index and phenotype in subjects with mild-to-moderate persistent asthma. J Allergy Clin Immunol. 2009;123(6):1328-34.e1.
  • Sutherland ER, Goleva E, Strand M, et al. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178(7):682–687.
  • Fingleton J, Travers J, Williams M, et al. Treatment responsiveness of phenotypes of symptomatic airways obstruction in adults. J Allergy Clin Immunol. 2015;136(3):601–609.
  • Invernizzi G, Ruprecht A, De Marco C, et al. Inhaled steroid/tobacco smoke particle interactions: a new light on steroid resistance. Resp Res. 2009;10(1):48.
  • Stott EJ, Chan WL, Mills KH, et al. Preliminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet. 1990;336(8730):1538–1541.
  • Barnes PJ. Glucocorticosteroids: current and future directions. Br J Pharmol. 2011;163(1):29–43.

• Comprehensive review of the mode of action of corticosteroids in asthma and COPD.

  • Clark AR, Belvisi MG. Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor. Pharmacol Ther. 2012;134(1):54–67.
  • Boardman C, Chachi L, Gavrila A, et al. Mechanisms of glucocorticoid action and insensitivity in airways disease. Pulm Pharmacol Ther. 2014;29(2):129–143.
  • Barnes PJ. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2013;131(3):636–645.

•• Comprehensive review of the mechanisms of corticosteroid resistance in asthma and COPD.

  • Keenan CR, Radojicic D, Li M, et al. Heterogeneity in mechanisms influencing glucocorticoid sensitivity: the need for a systems biology approach to treatment of glucocorticoid-resistant inflammation. Pharmacol Ther. 2015;150:81–93.
  • Vazquez-Tello A, Semlali A, Chakir J, et al. Induction of glucocorticoid receptor-beta expression in epithelial cells of asthmatic airways by T-helper type 17 cytokines. Clin Exp Allergy. 2010;40(9):1312–1322.
  • Livingston E, Darroch C, Chaudhuri R, et al. Glucocorticoid receptor alpha:beta ratio in blood mononuclear cells is reduced in cigarette smokers. J Allergy Clin Immunol. 2004;114:1475–1478.
  • Goleva E, Li L-B, Eves PT, et al. Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med. 2006;173(6):607–616.
  • Butler CA, McQuaid S, Taggart CC, et al. Glucocorticoid receptor β and histone deacetylase 1 and 2 expression in the airways of severe asthma. Thorax. 2012;67(5):392–398.
  • Sutherland ER, Goleva E, King TS, et al Cluster analysis of obesity and asthma phenotypes. PLoS ONE. 2012;7(5):e36631.
  • Kobayashi Y, Mercado N, Barnes PJ, et al. Defects of protein phosphatase 2A causes corticosteroid insensitivity in severe asthma. PLoS ONE. 2011;6(12):e27627.
  • Bhavsar P, Hew M, Khorasani N, et al. Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax. 2008;63(9):784–790.
  • Li JJ, Wang W, Baines KJ, et al. IL-27/IFN-γ induce MyD88-dependent steroid-resistant airway hyperresponsiveness by inhibiting glucocorticoid signaling in macrophages. J Immunol. 2010;185(7):4401–4409.
  • Li JJ, Tay HL, Maltby S, et al. MicroRNA-9 regulates steroid-resistant airway hyperresponsiveness by reducing protein phosphatase 2A activity. J Allergy Clin Immunol. 2015;136(2):462–473.
  • Cornejo S, Tantisira K, Raby BA, et al. Nuclear bioavailability of the glucocorticoid receptor in a pediatric asthma cohort with variable corticosteroid responsiveness. Pediatr Res. 2015;78:505–512. doi:10.1038/pr.2015.148. [ Epub ahead of print].
  • Hakonarson H, Bjornsdottir US, Halapi E, et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci U S A. 2005;102(41):14789–14794.
  • Loke T-K, Mallett KH, Ratoff J, et al. Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J Allergy Clin Immunol. 2006;118(2):368–375.
  • Ito K, Caramori G, Lim S, et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med. 2002;166(3):392–396.
  • Hew M, Bhavsar P, Torrego A, et al. Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med. 2006;174(2):134–141.
  • Cosío BG, Mann B, Ito K, et al. Histone acetylase and deacetylase activity in alveolar macrophages and blood mononocytes in asthma. Am J Respir Crit Care Med. 2004;170(2):141–147.
  • Ito K, Lim S, Caramori G, et al. Cigarette smoking reduces histone deacetylase 2 expression, enhances cytokine expression, and inhibits glucocorticoid actions in alveolar macrophages. FASEB J. 2001;15(6):1110–1112.
  • Cosio BG, Tsaprouni L, Ito K, et al. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004;200:689–695.
  • Hawrylowicz C, Richards D, Loke T-K, et al. A defect in corticosteroid-induced IL-10 production in T lymphocytes from corticosteroid-resistant asthmatic patients. J Allergy Clin Immunol. 2002;109(2):369–370.
  • Dejager L, Dendoncker K, Eggermont M, et al. Neutralizing TNF[alpha] restores glucocorticoid sensitivity in a mouse model of neutrophilic airway inflammation. Mucosal Immunol. 2015; doi:10.1038/mi.2015.12 Epub ahead of print
  • Bel EH, Sousa A, Fleming L, et al. Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). Thorax. 2011;66(10):910–917.
  • Schlender A, Alperin PE, Grossman HL, et al. Modeling the impact of increased adherence to asthma therapy. PLoS ONE. 2012;7(12):e51139.
  • Chaudhuri R, Livingston E, McMahon AD, et al. Effects of smoking cessation on lung function and airway inflammation in smokers with asthma. Am J Respir Crit Care Med. 2006;174(2):127–133.
  • Zhang Y, Leung DYM, Goleva E. Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma. J Allergy Clin Immunol. 2014;133(6):1744-52.e1.
  • Nanzer AM, Chambers ES, Ryanna K, et al. Enhanced production of IL-17A in patients with severe asthma is inhibited by 1α,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion. J Allergy Clin Immunol. 2013;132(2):297–304.

• Vitamin D3 supplementation in patients with corticosteroid resistant asthma demonstrated an increase in dexamethasone-induced IL-10 production in vitro as well as suppression of dexamethasone-induced IL-17A production.

  • Xystrakis E, Kusumakar S, Boswell S, et al. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest. 2006;116(1):146–155.
  • Nanzer AM, Chambers ES, Ryanna K, et al. The effects of calcitriol treatment in glucocorticoid-resistant asthma. J Allergy Clin Immunol. 2014;133(6):1755–7.e4.
  • Chambers ES, Nanzer AM, Pfeffer PE, et al. Distinct endotypes of steroid-resistant asthma characterized by IL-17A(high) and IFN-γ(high) immunophenotypes: Potential benefits of calcitriol. J Allergy Clin Immunol. 2015;136(3):628–637.
  • Castro M, King TS, Kunselman SJ, et al. Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin d levels: the VIDA randomized clinical trial. JAMA. 2014;311(20):2083-91(20), 2083-2091.
  • Martineau AR, Hanifa Y, Witt KD, et al. Double-blind randomised controlled trial of vitamin D3 supplementation for the prevention of acute respiratory infection in older adults and their carers (ViDiFlu). Thorax. 2015;70(10):953–960.
  • De Groot JC, Van Roon ENH, Storm H, et al. Vitamin D reduces eosinophilic airway inflammation in nonatopic asthma. J Allergy Clin Immunol. 2015;135(3):670-5.e3.
  • Roche N, Postma DS, Colice G, et al. Differential effects of inhaled corticosteroids in smokers/ex-smokers and nonsmokers with asthma. Am J Respir Crit Care Med. 2015;191(8):960–964.
  • Kobayashi Y, Mercado N, Miller-Larsson A, et al. Increased corticosteroid sensitivity by a long acting β2 agonist formoterol via β2 adrenoceptor independent protein phosphatase 2A activation. Pulm Pharm Therap. 2012;25(3):201–207.
  • Rossios C, To Y, Osoata G, et al. Corticosteroid insensitivity is reversed by formoterol via phosphoinositide-3-kinase inhibition. Br J Pharmacol. 2012;167(4):775–786.
  • Manetsch M, Ramsay EE, King EM, et al. Corticosteroids and β2-agonists upregulate mitogen-activated protein kinase phosphatase 1: in vitro mechanisms. Br J Pharmacol. 2012;166(7):2049–2059.
  • To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(7):897–904.
  • Spears M, Donnelly I, Jolly L, et al. Effect of low-dose theophylline plus beclometasone on lung function in smokers with asthma: a pilot study. Eur Respir J. 2009;33(5):1010–1017.

• An exploratory study examined the impact of low dose theophylline added to inhaled corticosteroid compared to inhaled corticosteroid alone in a group of smokers with asthma. The addition of theophylline to inhaled corticosteroid, at a dose titrated to provide a ‘subtherapeutic’ concentration, resulted in increased efficacy as measured by lung function and suggested the restoration of corticosteroid sensitivity in those treated with the combination.

  • Price D, Popov TA, Bjermer L, et al. Effect of montelukast for treatment of asthma in cigarette smokers. J Allergy Clin Immunol. 2013;131(3):763–771.
  • Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database of Systematic Reviews. 2014;1 Art. No.: CD003559doi:10.1002/14651858.CD003559.pub4
  • Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. New England J Med. 2014;371(13):1198–1207.
  • Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. New England J Med. 2014;371(13):1189–1197.
  • Cameron EJ, McSharry C, Chaudhuri R, et al. Long-term macrolide treatment of chronic inflammatory airway diseases: risks, benefits and future developments. Clin Exp Allergy. 2012;42(9):1302–1312.
  • Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-κB inhibition. J Pharmacol Exp Ther. 2013;345(1):76–84.
  • Kobayashi Y, Wada H, Rossios C, et al. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol. 2013;169(5):1024–1034.
  • Essilfie A-T, Horvat JC, Kim RY, et al. Macrolide therapy suppresses key features of experimental steroid-sensitive and steroid-insensitive asthma. Thorax. 2015;70(5):458–467.
  • Cameron EJ, Chaudhuri R, Mair F, et al. Randomised controlled trial of azithromycin in smokers with asthma. Eur Respir J. 2013;42(5):1412–1415.
  • Brusselle GG, VanderStichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329.
  • Balloy V, Deveaux A, Lebeaux D, et al. Azithromycin analogue CSY0073 attenuates lung inflammation induced by LPS challenge. Br J Pharmacol. 2014;171(7):1783–1794.
  • Bhavsar P, Khorasani N, Hew M, et al. Effect of p38 MAPK inhibition on corticosteroid suppression of cytokine release in severe asthma. Eur Respir J. 2010;35(4):750–756.
  • Guntur VP, Reinero CR. The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol. 2012;12(1):68–75.
  • Chung KF. p38 mitogen-activated protein kinase pathways in asthma and COPD. Chest. 2011;139(6):1470–1479.
  • Mercado N, Hakim A, Kobayashi Y, et al Restoration of corticosteroid sensitivity by p38 mitogen activated protein kinase inhibition in peripheral blood mononuclear cells from severe asthma. PLoS ONE. 2012;7(7):e41582.
  • Khorasani N, Baker J, Johnson M, et al. Reversal of corticosteroid insensitivity by p38 MAPK inhibition in peripheral blood mononuclear cells from COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:283–291.
  • Rhee CK, Kim JW, Park CK, et al. Effect of imatinib on airway smooth muscle thickening in a murine model of chronic asthma. Int Arch Allergy Immunol. 2011;155(3):243–251.
  • Humbert M, De Blay F, Garcia G, et al. Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics. Allergy. 2009;64(8):1194–1201.
  • Marwick JA, Caramori G, Casolari P, et al. A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2010;125(5):1146–1153.
  • Ito K, Caramori G, Adcock IM. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther. 2007;321(1):1–8.
  • Doukas J, Eide L, Stebbins K, et al. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther. 2009;328(3):758–765.
  • Mercado N, To Y, Ito K, et al. Nortriptyline reverses corticosteroid insensitivity by inhibition of phosphoinositide-3-kinase-delta. J Pharmacol Exp Ther. 2011;337:465–470.
  • Schuliga M. NF-kappaB signaling in chronic inflammatory airway disease. Biomolecules. 2015;5(3):1266–1283.
  • Page CP, Spina D. Selective PDE inhibitors as novel treatments for respiratory diseases. Curr Opin Pharmacol. 2012;12(3):275–286.

• Comprehensive review of selective PDE inhibitors as novel treatments for respiratory diseases.

  • Milara J, Lluch J, Almudever P, et al. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2014;134(2):314–322.
  • Chapman RW, House A, Richard J, et al Pharmacology of a potent and selective inhibitor of PDE4 for inhaled administration. Eur J Pharmacol. 2010;643(2-3):274–281.
  • Singh D, Petavy F, Macdonald A, et al. The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma. Resp Res. 2010;11(1):26.
  • Moretto N, Caruso P, Bosco R, et al. CHF6001 I: a novel highly potent and selective phosphodiesterase 4 inhibitor with robust anti-inflammatory activity and suitable for topical pulmonary administration. J Pharmacol Exp Ther. 2015;352(3):559–567.
  • Watz H, Mistry S, Lazaar A. investigators. I. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD. Pulm Pharmacol Ther. 2013;26(5):588–595.
  • Milara J, Navarro A, Almudéver P, et al. Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages. Clin Exp Allergy. 2011;41(4):535–546.
  • Franciosi LG, Diamant Z, Banner KH, et al. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials. Lancet Respir Med. 2013;1(9):714–727.
  • Spears M, McSharry C, Thomson NC. Peroxisome proliferator-activated receptor-gamma agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin Exp Allergy. 2006;36(12):1494–1504.
  • Lea S, Plumb J, Metcalfe H, et al. The effect of peroxisome proliferator-activated receptor-γ ligands on in vitro and in vivo models of COPD. Eur Respir J. 2014;43(2):409–420.
  • Spears M, Donnelly I, Jolly L, et al. Bronchodilatory effect of the PPAR-gamma agonist rosiglitazone in smokers with asthma. Clin Pharmacol Ther. 2009;86(1):49–53.
  • Hothersall E, McSharry C, Thomson NC. Potential therapeutic role for statins in respiratory disease. Thorax. 2006;61(8):729–734.
  • Yeganeh B, Wiechec E, Ande S, et al. Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease. Pharmacol Ther. 2014;143(1):87–110.
  • McKay A, Leung BP, McInnes IB, et al. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol. 2004;172(5):2903–2908.
  • Lee J-H, Lee D-S, Kim E-K, et al. Simvastatin inhibits cigarette smoking-induced emphysema and pulmonary hypertension in rat lungs. Am J Respir Crit Care Med. 2005;172(8):987–993.
  • Samson K, Minoguchi K, Tanaka A, et al. Inhibitory effects of fluvastatin on cytokine and chemokine production by peripheral blood mononuclear cells in patients with allergic asthma. Clin Exp Allergy. 2006;36(4):475–482.
  • Maneechotesuwan K, Ekjiratrakul W, Kasetsinsombat K, et al. Statins enhance the anti-inflammatory effects of inhaled corticosteroids in asthmatic patients through increased induction of indoleamine 2, 3-dioxygenase. J Allergy Clin Immunol. 2010;126(4):754–762.
  • Braganza G, Chaudhuri R, McSharry C, et al Effects of short-term treatment with atorvastatin in smokers with asthma - a randomized controlled trial. BMC Pulm Med. 2011;11:16.
  • Thomson NC, Charron CE, Chaudhuri R, et al. Atorvastatin in combination with inhaled beclometasone modulates inflammatory sputum mediators in smokers with asthma. Pulm Pharmacol Ther. 2015;31:1–8.

• Short-term treatment with atorvastatin alone or in combination with inhaled beclometasone reduces several sputum cytokines, chemokines and growth factors concentrations unresponsive to inhaled corticosteroids alone, in smokers with asthma.

  • Maneechotesuwan K, Kasetsinsombat K, Wongkajornsilp A, et al. Decreased indoleamine 2,3-dioxygenase activity and IL-10/IL-17A ratio in patients with COPD. Thorax. 2013;68(4):330–337.
  • Glasser SW, Senft P, Maxfield MD, et al. Genetic replacement of surfactant protein-C reduces respiratory syncytial virus induced lung injury. Respir Res. 2013;14(1):137.
  • Nair P, Gaga M, Zervas E, et al. Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2012;42(7):1097–1103.
  • Rennard SI, Dale DC, Donohue JF, et al. CXCR2 antagonist MK-7123—A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;191(9):1001–1011.
  • Chaudhuri R, Norris V, Kelly K, et al. Effects of a FLAP inhibitor, GSK2190915, in asthmatics with high sputum neutrophils. Pulm Pharmacol Ther. 2014;27(1):62–69.
  • Chesné J, Braza F, Mahay G, et al. IL-17 in severe asthma. where do we stand?. Am J Respir Crit Care Med. 2014;190(10):1094–1101.
  • Busse WW, Holgate S, Kerwin E, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med. 2013;188(11):1294–1302.
  • Wenzel SE, Barnes PJ, Bleecker ER, et al. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-alpha blockade in severe persistent asthma. Am J Respir Crit Care Med. 2009;179(7):549–558.
  • Holgate ST, Noonan M, Chanez P, et al. Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. Eur Respir J. 2011;37(6):1352–1359.
  • Jarjour NN, Erzurum SC, Bleecker ER, et al. Severe asthma: lessons learned from the national heart, lung, and blood institute severe asthma research program. Am J Respir Crit Care Med. 2012;185(4):356–362.
  • The ENFUMOSA Study Group. The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European network for understanding mechanisms of severe asthma. Eur Respir J. 2003;22(3):470–477.
  • Shaw DE, Sousa AR, Fowler SJ, et al. Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015;46(5):1308–1321.
  • Heaney LG, Djukanovic R, Woodcock A, et al. Research in progress: medical research council United Kingdom refractory asthma stratification programme (RASP-UK). Thorax. 2015; doi:10.1136/thoraxjnl-2015-207326 [ Epub ahead of print].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.